NCT07010978 Towards Testing the Effectiveness of Recovery Community Centers (RCCs)
| NCT ID | NCT07010978 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Opioid Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 128 participants |
| Start Date | 2025-08-20 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 128 participants in total. It began in 2025-08-20 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this pilot randomized clinical trial is to prepare for a larger randomized clinical trial (RCT) and collect some early data to learn if the intervention can help people who use medications for opioid use disorder (MOUD). The main questions it aims to answer are: 1. Is it feasible to recruit and randomize people to both treatment groups? 2. Does linking people to recovery community centers lead to better recovery outcomes? Researchers will compare linking people to recovery community centers (RCC) to enhanced treatment as usual to see if recovery outcomes are different. In one group, participants will learn about their local RCC and will be asked to visit their local RCC on at least two days and write about their experiences. In the other group, participants will learn about different recovery activities, pick any two, and do the activities of their choice on at least two days. They will also be asked to write about their experiences. People in both groups will answer online survey questions about their recovery outcomes and well-being in five surveys over one year.
Eligibility Criteria
Inclusion Criteria: * 18+ years of age * Uses MOUD (at enrollment; participants may stop using MOUD subsequently) to treat OUD * Receives MOUD from a clinic/pharmacy located within 15 miles of an RCC vetted by our study team, which serves a Black community (i.e., defined as being located in a ZIP code where ≥27% of the residents are Black, as per US Census) * Is willing and able to engage in study procedures (i.e., online surveys, timeline follow back interview) * Is willing to be randomized Exclusion Criteria: \- Has visited a vetted RCC during the past 3 months
Contact & Investigator
Bettina Hoeppner, Ph.D., M.S.
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT07010978 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Opioid Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07010978 currently recruiting?
Yes, NCT07010978 is actively recruiting participants. Contact the research team at bhoeppner@mgh.harvard.edu for enrollment information.
Where is the NCT07010978 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT07010978 clinical trial?
NCT07010978 is sponsored by Massachusetts General Hospital. The principal investigator is Bettina Hoeppner, Ph.D., M.S. at Massachusetts General Hospital. The trial plans to enroll 128 participants.